About This Video
Entheon Biomedical Corp. is a newly listed public company on the Canadian Securities Exchange stock market under the symbol ENBI. Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
Learn more about Entheon Biomedical at https://thecse.com/en/listings/life-sciences/entheon-biomedical-corp
Subscribe for more great CSE insights and interviews here: https://bit.ly/CSETVSubscribe
STAY CONNECTED WITH THE CSE
=============================
- PODCAST: https://blog.thecse.com/pe-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
MB01JW2HHZJG0YD
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
hi welcome to newly listed i'm your host barry miller and today i'm here with timothy co from ethion biomedical newly listed on the canadian securities exchange welcome to the show timothy hey thank you barrington it's a pleasure to be here tell us a little bit about your company what do you mean absolutely first good thank you for the opportunity so anthony on biomedical we're doing drug discovery in the
psychedelic field yeah to address an absolutely massive problem so drug addiction i lost my brother to drug addiction in march of last year and yeah it was just a case study in the limitations of conventional methods of treating drug addiction and yeah i think as a society we've come to expect have expectations around drug addiction where success rates of current treatments are so low that we
often see people afflicted with drug addiction as you know a life sentence that potentially will become a fatal for them so anthony was created to directly address that and to invert the expectations around drug addiction going from something that's you know really low levels of efficacy to something that really addresses at the core of the underlying issues that you know spur that drug seeking drug addictive
behavior we're seeing a lot of companies and i mean we at the canadian securities exchange we're seeing a lot of companies that are beginning to list that fall under this category what is your differentiator when it comes to this operation yeah absolutely i think we have a number of key differentiators you know first of which is the sort of i guess the skill and adeptness of our team if you look at
our scientific advisory board it is comprised of some of the most well-known and accomplished names in psychedelic research space yeah and these people represent johns hopkins university the imperial college of london as well as the ubc pharmacology department and i think all together it really represents you know the leading edge of thought in that space and i guess another really a key part of what we do
is the molecule that we've decided to use we've decided to use dmt for the purposes of treating addiction and dmt for those that aren't super aware is the you know active psychoactive in ayahuasca and i guess people are more generally aware of what ayahuasca is but it's a you know psychoactive brew that's been used for millennia to treat all matters of i guess diseases despair matters of a psychological or emotional
nature and so dmt is massively powerful it's a really well tolerated psychoactive molecule and of course you know we can't bring along that that sort of organic jungle brew for the purpose of treating these medical conditions so what we're doing to adhere to the you know rigorous regulatory sort of framework that exists we're taking pure synthetic dmt and finding a way to administer it gradually safely and in a really well
tolerated way and we think there are some really key value features to that that are not seen in you know psilocybin or lsd namely the ability to really tailor the way that the experience is shaped as well as to keep that person in that therapeutically useful dose range for a set period of time that is very adjustable and can be titrated in the event that a negative adverse reaction
takes place unlike psilocybin which can take anywhere from four to eight hours during which time if that person has a you know unusual or negative experience it's really hard to bring them down we think from the perspective of safety and scalability it's really useful to have something that you know can be controlled and shortened in terms of its duration and in the event that that experience becomes bad we can titrate
it or cease it all together and have that person return to a functional baseline without any sort of traumatic event taking place wow this is that's that's really really good and you're you're filling a void and filling a really big niche earlier you mentioned some members of your team i was wondering if you could elaborate and tell us a little bit about the people that you work with
yeah absolutely on the management side we have dr andrew hegley he represents the ubc pharmacology department he's an adjunct professor there he worked previously in cannabis alongside some of our advisors like dr michael walker and louis franciosi when combined they represent a broad history of experience with you know bringing drugs from so concept all the way to market market authorization to sell
and so yeah represent that really strong pre-clinical and pharmacological team and then supported by you know some of those names that are you know ring bells in the psychedelic space such as robin card harris from the imperial college of london he runs their psychedelic research unit there and they're at the leading edge of the science as it pertains to you know psychedelic research and specifically dmt research
and they've been invaluable in informing our protocols and the very specifics of how the drug is administered and on the american side we have people like matthew johnson he's you know also really well renowned psychedelic researcher who's done amazing work specifically in addiction with regard to nicotine cessation as well as investigation of other types of addiction so you know and of course people like
christopher timmerman melanie you know that the list goes on and you know aside from just being people of high name recognition they have been really instrumental in defining the particulars about how best to structure a clinically useful addiction cessation type of protocol and for current investors and soon to be investors are there any milestones that you're able to talk about yeah absolutely so we're blessed to
have some really amazing partners that are working with us and so critical to the clinical trials drug approval process are gmp so good manufacturing practices so pure synthetic drug supply we anticipate the receipt of our first research batch quite soon as well as you know the commencement of our human safety trial with the people from chdr the center for human drug research massively
you know accomplished research group out of the netherlands we're gonna be conducting our first human clinical trial in estimated q2 of 2021 and that will be instrumental in establishing that very basic safety that's necessary to serve as that sort of pharmacological basis that we can then submit to regulators and last but not least why did you choose to go public absolutely it's a really good question
it's been volleyed at us quite often but you know i think we understand that the realities of the drug development process are very capital intensive very time and capital intensive and we believe that the strength of our clinical development pathway has enough significant de-risking milestones that will highlight to investors that yes as these guys and gals move along this process and demonstrate you know pretty empirically that
the path they've chosen is in in fact safe and logical you know we will inspire investor confidence and allow us to raise additional funds for our clinical development you know at higher valuations thereby you know supporting or benefiting our initial shareholders and giving the market opportunities to get involved in what we believe is a pretty revolutionary drug product well timothy on behalf of the canadian securities
exchange i want to say thank you thank you for sharing your story with us thank you for taking the time and we wish you nothing but continued success for those people that wish to trade your stock what is your symbol we are trading under enbei and they can be found at the canadian securities exchange thank you once again this has been an episode of newly listed
you



